CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +83,145 | $3.99 | $332K | 605,268 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Sale 10b5-1 | −308,477 | $16.91 | $5.2M | 296,791 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −834 | 0 | ||
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −20,834 | 0 | ||
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −49,480 | 0 | ||
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −34,375 | 0 | ||
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −119,809 | 17,161 | ||
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −83,145 | 116,404 | ||
| 2025-11-20 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +133,032 | $8.46 | $1.1M | 525,755 |
| 2025-11-20 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +68,961 | $12.14 | $837K | 594,716 |
| 2025-11-20 | BENZENO SHARON Chief Commercial Ofc Imm Med | Sale 10b5-1 | −297,925 | $16.54 | $4.9M | 296,791 |
| 2025-11-20 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −133,032 | 66,517 | ||
| 2025-11-20 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −68,961 | 136,970 | ||
| 2025-11-17 | PISKEL KYLE Chief Financial Officer | Sale | −238 | $14.05 | $3K | 269,343 |
| 2025-11-12 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −1,867 | $15.00 | $28K | 2,869,975 |
| 2025-11-11 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −1,237 | $14.57 | $18K | 2,871,851 |
| 2025-11-10 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −10,000 | $14.82 | $148K | 1,269,524 |
| 2025-11-10 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −86,161 | $14.73 | $1.3M | 2,873,088 |
| 2025-05-16 | PISKEL KYLE Chief Financial Officer | Sale | −1,929 | $8.89 | $17K | 269,581 |
| 2025-05-16 | PISKEL KYLE Chief Financial Officer | Sale | −1,929 | $8.89 | $17K | 277,396 |
Page 25 of 120 · 2,386 trades